Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of camrelizumab, an anti-PD-1 monoclonal antibody, and bevacizumab, an anti-VEGF monoclonal antibody. Camrelizumab enhances T-cell immune responses against cancer cells by blocking the PD-1 pathway, while bevacizumab prevents the growth of new blood vessels that tumors need to grow by targeting VEGF. This dual approach aims to simultaneously activate the immune system against cancer cells while cutting off the tumor's blood supply.
- Other names
- PD-1 inhibitor + bevacizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on camrelizumab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + bevacizumab.